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Abstract
Background: Chronic kidney disease (CKD) has a high global prevalence and large 
unmet need. Central to developing new CKD therapies are in vivo models in CKD. 
However, next- generation antibody, protein, and gene therapies are highly specific, 
meaning some do not cross- react with rodent targets. This complicates preclinical 
development, as established in vivo rodent models cannot be utilized unless tool 
therapeutics are also developed. Tool compounds can be difficult to develop and, if 
available, typically have different epitopes, sequences, and/or altered affinity, mak-
ing it unclear how efficacious the lead therapeutic may be, or what dosing regimen to 
investigate. To address this, we aimed to develop a nonhuman primate model of CKD.
Methods: In vivo rodent unilateral ureteral obstruction (UUO) models kidney fibrosis 
and is commonly used due to its rapidity, consistency, and ease. We describe translation 
of this model to the cynomolgus monkey, specifically optimizing the model duration to 
allow adequate time for assessment of novel therapeutics prior to the fibrotic plateau.
Results: We demonstrated that disease developed more slowly in cynomolgus mon-
keys than in rodents post- UUO, with advanced fibrosis developing by 6 weeks. The 
tubulointerstitial fibrosis in cynomolgus monkeys was more consistent with human 
obstructive disease than in rodents, having a more aggressive tubular basement ex-
pansion and a higher fibroblast infiltration. The fibrosis was also associated with in-
creased transglutaminase activity, consistent with that seen in patients with CKD.
Conclusion: This cynomolgus monkey UUO model can be used to test potential 
human- specific therapeutics in kidney fibrosis.
K E Y W O R D S
animal models, fibrosis, kidney, nonhuman primates, transglutaminase
1  | INTRODUC TION
Chronic kidney disease (CKD) is one of the most common diseases 
worldwide with kidney fibrosis being a histological hallmark.1,2 
Several animal models of CKD have been developed to understand 
pathogenesis and verify disease targets for therapeutic treatment. 
Unilateral ureteral obstruction (UUO) is a model resembling human 
obstructive nephropathy. Although it is not a common cause of 
human renal disease, it is a well- recognized and frequently used 
model of kidney damage with subsequent fibrosis development.3- 5 
By ligating a ureter of one kidney, the build- up of urine elevates in-
tratubular pressure; this results in reduction in renal blood flow and 
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glomerular filtration rate, as well as other changes such as intersti-
tial inflammation, tubular dilation, tubular atrophy, and, ultimately, 
fibrosis. Rodent UUO models have been utilized to investigate 
mechanisms of tubulointerstitial fibrosis, with severe fibrosis being 
detected within 21 days.6,7
Development of fibrosis in the rodent UUO model is associated 
with changes in extracellular transglutaminase (TG) 28 and is a hall-
mark of human disease pathology.9 TG2 is a calcium- dependent en-
zyme that crosslinks extracellular matrix (ECM) proteins to form a 
stable and proteolytic resistant ε(γ- glutamyl)- lysine dipeptide cross-
link.10 This increased crosslinking in ECM accelerates the rate of ECM 
deposition, while making it less susceptible to degradation by ECM 
proteases. Increases in extracellular TG2 expression, TG activity, and 
ε(γ- glutamyl)- lysine dipeptide crosslinks have been demonstrated in 
all types of human CKD, and are highly correlated with fibrosis lev-
els.9 Studies performed using rodent models of kidney fibrosis have 
shown increased TG2 and that blocking its activity slows renal fi-
brosis.8,11- 13 A study is currently underway to evaluate inhibition of 
TG2 in patients with CKD (NCT04335578). TG2 is therefore a useful 
mechanistic tool to evaluate if the pathological processes of CKD 
occurring in an in vivo model are consistent with those in humans.
Although some proteins are homologous between species, 
antibodies targeting functional human epitopes (i.e., therapeutic 
antibodies) can be highly species- specific as they often recognize 
conformational epitopes, whereby changes in a single amino acid 
in the epitope can raise affinity and lower half- maximal inhibitory 
concentration (IC50) significantly. Therefore, antibodies optimized 
for human proteins may not sufficiently cross- react with other 
species to allow testing in commonly used rodent in vivo models. 
An option to mitigate this is to use a surrogate tool antibody; how-
ever, binding at a different epitope may complicate interpretation 
of data, provide different pharmacokinetics and thus, less valuable 
translational data to predict efficacious doses in early clinical stud-
ies. It is becoming increasingly important to use models in species 
with high homology and close physiology to humans to evaluate 
next- generation therapeutic antibodies and other modalities where 
species homology plays a significant role such as gene, small in-
terfering RNA (siRNA), and oligonucleotide therapies. The non-
human primates (NHP) most commonly used in medical research 
are from the genus Macaca, or more specifically the cynomolgus 
monkey. Their consensus with the human proteome14 allows a 
high degree of cross- reactivity, making them a suitable species for 
studies with highly specific antibodies or other new therapeutic 
modalities. Models of liver15 and lung fibrosis16 have been estab-
lished in cynomolgus monkeys and there are NHP models of renal 
transplantation/rejection.17 However, to date, there are no models 
of renal fibrosis in NHP. Therefore, we hypothesized that a cyno-
molgus monkey UUO model could be developed and validated. The 
UUO model surgery is simple (compared with other models such as 
5/6th subtotal nephrectomy) and the remaining functional kidney 
prevents problems with organ failure and any associated welfare 
issues such as end- stage renal failure. Translating the UUO model 
from mice to rats to rabbits was relatively consistent and quick; 
thus, we did not anticipate issues in translating the model to cyno-
molgus monkeys. Given the biggest variable between species when 
using the UUO model is the time to develop fibrosis consistent with 
end- stage renal disease, we undertook a time- course evaluation of 
tubulointerstitial fibrosis post- UUO to understand the optimal du-
ration of the model and evaluate expression of a human- relevant 
pathological process currently being tested in the clinic: TG2.
2  | MATERIAL S AND METHODS
2.1 | Animal study
Fourteen male cynomolgus monkeys (Hainan Jingang Biotech Co. 
Ltd., China) were used in the study. All animals were tuberculosis- 
negative and free of viral, bacterial, or parasitic infections (including 
simian immunodeficiency virus, respiratory syncytial virus, simian- 
T- lymphotropic virus, tuberculosis, Schmallenberg virus, shigellosis, 
and salmonella). Adult monkeys (aged 7– 8 years) were used in this 
study to more accurately model human disease. Common tests for 
kidney disease were performed to ensure that the animals had no 
proteinuria (urinary protein <10 mg/dl, test with visual urinary test 
strip) or loss of renal function (serum creatinine <100 µmol/L, blood 
urea nitrogen <9 mmol/L) at study initiation.
Each monkey was housed in a stainless steel cage with a mini-
mum living area of length 160 cm × depth 80 cm × height 190 cm at 
18– 29°C with a relative humidity of 40%– 70% and had access to the 
exercise cage sized 480 × 80 × 190 cm for 24 h each week (1 animal 
per cage). Monkeys had free access to monkey chow (Guangzhou 
Guolong Science & Technology Co. Ltd., China) and municipal tap 
water meeting drinking standards; vegetables and fruit treats were 
also given daily to stimulate their appetite.
The 14 cynomolgus monkeys were randomized (simple random-
ization method) into 5 groups: 1 consisting of 2 sham- operated an-
imals (harvested at week 6; one time point was sufficient for the 
sham population, to confirm that no fibrosis occurred at the max-
imum time point) and 4 groups of 3 animals undergoing UUO and 
kept for experimental periods of 3, 4, 5, or 6 weeks after surgery. 
Sham animals received laparotomy only and animals in the UUO 
groups had the left ureter occluded with a double silk tie. Animals 
were fasted for 12 h and water withheld for 3 h prior to general an-
esthesia. Anesthesia was induced by intramuscular (IM) injection of 
5 mg/kg Zoletil 50 (Virbac, Carros, France) initially and maintained 
using 5% isoflurane inhalation. Prior to a midline incision in the ab-
dominal wall, fur was shaved and skin disinfected. The ureter of the 
left kidney was dissected and ligated at 2 adjacent points by silk ties 
and the abdominal wall subsequently closed. To minimize infection, 
25 000 IU/kg of penicillin was given by IM injection twice daily for 
3 days. The analgesia regimen applied is listed in Table 1. Animals 
were closely monitored post- surgery; their appearance, body 
weight, temperature, respiratory rate, and behavior were assessed 
daily and their skin wound checked by an onsite vet every day until 
it healed. All UUO animals were provided with soft bedding after 
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surgery until normal behavior resumed (scored and recorded during 
each observation). In general, the UUO surgical procedure was as-
sociated with moderate pain, and all animals recovered within a few 
days. At harvest, animals were euthanized by intravenous injection 
of 80 mg/kg pentobarbital, and kidneys dissected longitudinally and 
each half cut into 4 segments. One segment from each half kidney 
was fixed in 10% neutral formalin solution and embedded in paraffin 
blocks. The other segments were snap frozen and used for in situ TG 
activity, extracellular TG2 staining, and hydroxyproline detection. 
Researchers performing sample analysis did not know the group al-
location until data were generated.
2.2 | Picrosirius red and Masson's trichrome stain
Neutral- buffered, formalin- fixed, paraffin- embedded 4 µm sections 
were dewaxed and rehydrated. Nuclei were stained with Weigert's 
hematoxylin (Sigma Aldrich, UK), washed in water, and stained in 
Picrosirius red (PSR) solution for 1 h prior to being washed in acidi-
fied water. Sections were dehydrated and cleaned using a series of 
alcohols and xylenes and then mounted in dibutylphthalate polysty-
rene xylene (DPX). Masson's trichrome stain was then performed 
using a kit (Sigma Aldrich, UK) as per manufacturer instructions 
(stains collagenous material blue, nuclei brown and fibers, erythro-
cytes and elastin red/pink).
2.3 | In situ TG activity
Detection of in situ TG activity was performed as described pre-
viously13 with some modification. Frozen kidney tissues were 
mounted in optimal cutting temperature (OCT) mounting media 
(VWR International, UK) and cut at 10 µm thickness. Unfixed sec-
tions were washed in phosphate- buffered saline (PBS) and incu-
bated with reconstitution PBS made up of 5% bovine serum albumin 
(BSA) with protease inhibitors (Sigma Aldrich, UK) for 30 min at 
room temperature. Sections were then washed twice with PBS prior 
to being incubated with reaction mix containing 5 mmol/L CaCl2, 
1 mmol/L dithiothreitol, and 0.5 mmol/L biotin cadaverine (Thermo 
Fisher Scientific, UK) with protease inhibitors in 50 mmol/L Tris (pH 
7.4) for 30 min at 37°C. A negative control in which CaCl2 was re-
placed with 10 mmol/L ethylenediaminetetraacetic acid was used. 
Slides were washed 3 times with PBS, fixed in cold acetone for 
5 min, and air dried. Sections were washed in PBS and incubated 
with a 1 in 500 dilution of streptavidin- Alexa 555 (Thermo Fisher 
Scientific, UK) for 1 h at 37°C. Slides were then washed 3 times 
with PBS and mounted with anti- fade mounting media containing 
4′,6- diamidino- 2- phenylindole (DAPI).
2.4 | Extracellular TG2 antigen staining
Immunodetection of extracellular TG2 was performed as previously 
described.9,12 Frozen kidney tissues were mounted in OCT mounting 
media and cut at 10 µm thickness. Unfixed sections were washed in 
PBS, and blocked in PBS buffer made up of 5% BSA with protease 
inhibitors for 30 min at room temperature prior to being incubated 
with a mouse anti- human TG2 antibody (IA12; generated recom-
binantly in- house at UCB, using the sequences described in patent 
WO/2013/17522918 and used previously for analytical work8) at a 
concentration of 30 µg/mL for 1 h at 37°C. Sections were washed 3 
times with PBS, fixed in cold acetone for 5 min, and air dried. These 
were then washed with PBS before a goat anti- mouse Alexa 488 anti-
body (Thermo Fisher Scientific, UK), diluted 1 in 500 in 5% BSA/PBS, 
was added. After incubation for 1 h at 37°C, sections were washed in 
PBS and mounted with anti- fade mounting medium containing DAPI.
2.5 | Measurement of kidney fibrosis levels, in situ 
TG activity and extracellular TG2 protein
Images of PSR- stained sections were downloaded onto Tissue 
Studio (Definiens Inc., USA). Selection of the region of interest (ROI) 
was performed on sections, separating out the cortex for analysis 
(Figure 1A). Definiens Stain Picker options and “computer training/
learning” methods were used to generate an algorithm to identify col-
lagen staining (red and intense staining overlaid in orange) and nuclei 
(blue) (Figure 1B,C). Definiens automatically calculates the areas of 
the ROI, and the 3 marker areas for each slide. The ratio of collagen 
area to cortical area was calculated to represent the fibrotic index.
To analyze images of TG activity and extracellular TG2 protein, 
the dedicated Definiens Fluorescence workspace was used. ROI 
detection was performed automatically and corrected manually to 
remove the medulla from analysis. Marker detection was then per-
formed on different image layers depending on the marker. DAPI 
nuclear stain (blue) was projected as green and analyzed on layer 1 
(green overlay), and TG activity (yellow) or extracellular TG2 (green) 
was projected as red and analyzed on layer 2 (red overlay, intense 
staining overlaid in yellow) (Figure 1D). The area of staining was de-
termined by the Definiens software, and levels of TG activity or ex-
tracellular TG2 were calculated using the ratio of the staining area to 
DAPI nuclear stain area.
Drug Dose Dosing time Frequency Duration
Codeine 0.5 mg/kg, PO 2 h before surgery 3 times daily 3 days
Lornoxicam 0.7 mg/kg, IM 20 min before surgery Once daily — 
Lornoxicam 0.35 mg/kg, IM 11 h post- surgery Twice daily 3 days
Abbreviations: IM, intramuscular; PO, oral administration.
TA B L E  1   Analgesia regimen
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2.6 | Hydroxyproline analysis
Kidney homogenates containing 5 mg of protein per sample were hy-
drolyzed in 6 mol/L hydrochloric acid at 110°C for 24 h. These were 
centrifuged at 18 000 g for 2 min and the supernatant transferred 
to clean tubes and freeze dried. Samples were resuspended in 500 µl 
of lithium loading buffer (Biochrom, UK) and 30 µl fractionated using 
a lithium chloride gradient on a Biochrom 30+ amino acid analyzer 
using the manufacturer's standard protocol and expressed as µmol/
mg protein.
2.7 | Measurement of ε- (γ- glutamyl)- lysine crosslink
Kidney homogenate containing 10 mg of protein from each animal 
was subjected to exhaustive proteolytic digestion with subtilisin, 
pronase, leucine amino peptidase, prolidase, and carboxypeptidase 
Y. Measurement of ε- (γ- glutamyl)- lysine crosslinks was performed 
using cation exchange chromatography on an amino acid analyzer 
(Biochrom, UK).
2.8 | Statistical analysis
Raw data are shown with each symbol representing one animal. 
Data analyses were performed using one- way analysis of variance 
(ANOVA) by a Fisher's least significant difference multiple compari-




At 6 weeks, UUO in cynomolgus monkeys caused changes mainly 
in the tubulointerstitium, as expected. From week 3 onwards, 
under low magnification (Figure 2, upper panel), key changes ob-
served were tubular dilation and increased collagen accumula-
tion, shown as blue on the Masson's trichrome stained images. 
Using higher- power magnification (Figure 2, lower panel), it was 
possible to observe flattened and elongated tubular epithelial 
cells leading to dilated tubules with loss of the brush border. 
Thickening of the tubular basement membrane was particularly 
clear and notably in excess of that seen in rodent UUO mod-
els, as well as increased cell numbers in the expanded tubuloint-
erstitial space. Compared with the sham, these changes were 
relatively mild in the 3- week group, but progressed in severity 
through weeks 4 and 5, peaking at week 6. Of note, there was 
significant expansion of the tubular basement between weeks 3 
and 4, which seemed to expand little after week 4 where tubular 
destruction and atrophy became the main histological changes. 
Fibrotic changes, especially tubulointerstitial expansion, was 
confirmed by PSR- stained sections (Figure 3). Image analysis was 
performed to quantify levels of fibrosis. All UUO groups had in-
creased fibrosis, reaching significance in the 4- and 6- week UUO 
groups (Figure 4A).
Hydroxyproline is a major component of collagen and can 
be used as an easily quantifiable surrogate of the total amount 
of collagen present in the kidney. In this cynomolgus monkey 
F I G U R E  1   Example of ROI selection (A), cellular analysis on normal tissue (B) and fibrotic tissue (C), and analysis on a TG activity image 
(D). ROI selection (A) is demonstrated by the autodetected tissue area (red) and the manually excluded medulla area (gray). Red collagen 
stain is labeled in red with intense staining overlaid in orange by cellular analysis. Nuclei are marked in blue (B, C). TG activity shown in 
yellow is covered by red and blue nuclei overlaid in green (D). ROI, region of interest; TG, transglutaminase
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model, significantly elevated hydroxyproline was detected in the 
UUO kidneys from week 4 onwards (Figure 4B). Compared with 
the sham, levels of hydroxyproline were increased by 1.5- fold at 
week 3, more than double at week 4 and peaked with a 2.6- fold 
change at weeks 5 and 6.
3.2 | In situ TG activity, extracellular TG2 
expression and levels of ε- (γ- glutamyl)- lysine crosslink
In the healthy (sham) kidney, low TG activity was seen in the glomer-
uli and tubular basement membrane/tubulointerstitial space, based 
F I G U R E  2   Progression of kidney fibrosis post- UUO, with Masson's trichrome staining. Kidney segments were fixed in 10% neutral 
formalin solution for 24 h and blocked. Paraffin embedded 4 µm tissue sections were stained for Masson's trichrome. Collagen is stained 
blue, nuclei brown, and fiber, erythrocytes, and elastin red/pink. UUO, unilateral ureteral obstruction
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on incorporation of the labeled TG substrate (biotin cadaverine) 
(Figure 5A). Activity increased 3 weeks post- UUO, with an elevation 
in substrate incorporation in the expanded tubulointerstitial space at 
4 weeks post- UUO. TG activity at 5 and 6 weeks post- UUO contin-
ued to increase (Figure 5A) in contrast to TG2 extracellular antigen, 
which plateaued at weeks 5 and 6 (Figure 5B). When image analysis 
was performed to quantify changes in TG activity, 3- , 6- , and 8- fold 
increases were seen at weeks 4, 5, and 6, respectively (Figure 5C).
In the kidneys of healthy (sham) cynomolgus monkeys, small 
amounts of extracellular TG2 were detected and located in the tubular 
basement membrane/tubulointerstitial space, periglomerular area and 
mesangial matrix (Figure 5B). In the kidneys of cynomolgus monkeys 
F I G U R E  3   Progression of kidney fibrosis post- UUO, with PSR staining. Kidney segments were fixed in 10% neutral formalin solution for 
24 h and blocked. Paraffin embedded 4 µm tissue sections were stained with PSR. Collagen is stained in red and cytoplasm in yellow. PSR, 
picrosirius red; UUO, unilateral ureteral obstruction
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with UUO, changes in extracellular TG2 expression were mainly fo-
cused around tubules and associated with the tubular basement 
membrane (Figure 5B). Elevation in extracellular TG2 antigen reached 
a maximum at 4 weeks post- UUO and remained at that level for the 
remainder of the study. Quantification of the image analysis indicated 
that extracellular TG2 increased in the kidneys of cynomolgus mon-
keys with UUO from 3 weeks onwards, with significant changes com-
pared with the sham group at 4, 5, and 6 weeks post- UUO (Figure 5D).
Analysis of ε- (γ- glutamyl)- lysine crosslink in kidneys with UUO 
showed a progressive trend of elevated crosslink dipeptide that 
reached a maximum at 5 weeks post- UUO and remained high to 
week 6 (Figure 5E).
3.3 | Correlations between levels of in situ TG 
activity versus ε- (γ- glutamyl)- lysine crosslink and 
hydroxyproline
Correlation between in situ TG activity and ε- (γ- glutamyl)- lysine 
crosslink was r = .52 (Figure 6A). There was also a correlation be-
tween in situ TG activity and hydroxyproline, strongly linking the 
accumulation of collagen with TG2 in this model (r = .82, Figure 6B).
4  | DISCUSSION
This study sought to transfer the UUO model of CKD from rodents 
to cynomolgus monkeys, with the aim of allowing development 
of human- specific therapeutics, not cross- reactive with rodents 
and with a novel mode of action, for which in vivo pharmacologi-
cal data are essential to define dosing for phase I human studies. 
Understanding the time course of the disease process was key to 
allowing optimal selection of study duration and relating this to 
changes in collagen levels (and thus fibrosis), while using TG2 as 
an exemplar molecule of clinical stage target in CKD. The model 
was developed in adult animals to assist with translation, as CKD 
is typically a disease of later life in which changes occur in multiple 
parameters associated with fibrosis, including cell senescence,19,20 
promoter methylation,21 ECM homeostasis,22 and hemodynamics.23
Overall, these data demonstrate a clear development of tubu-
lointerstitial fibrosis over the 3- to 6- week study period, although 
data from the different methods used to assess the extent of fibrosis 
in this study were not totally aligned. Manual assessment of the sec-
tions would suggest fibrosis progressed over the 6- week study pe-
riod, approaching end- stage remodeling around or just after week 6. 
Image analysis of PSR suggested that the level of interstitial collagens 
plateau from week 4 onwards, whereas total kidney hydroxyproline 
is progressive until week 5. In terms of TG2, the level of activity pro-
gressed over the 6 weeks, with maximum extracellular TG2 antigen 
reached by week 4, and the formation of ε- (γ- glutamyl)- lysine peak-
ing at week 5. This poses the question of the optimal time to run the 
model when being used to test interventional efficacy. It is generally 
accepted that the level of fibrosis will ultimately reach a plateau in 
nonfunctional models such as the UUO. Therefore, model duration 
must be optimized to allow the maximum window for measurement 
of interventional success before the linear formation of scar tissue 
declines and hides any beneficial effect on slowing progression of 
fibrosis. Based on the composite data here, a 4- week model in aged 
cynomolgus monkeys would provide the optimal balance between 
the disease window and the slowing of histological and mechanistic 
changes that underpin fibrosis. However, given the heterogeneity of 
data due to the intentionally small animal numbers used, it is possi-
ble that the optimal duration of this model to maximize the disease 
window could be 5 weeks.
Although the data allow us to conclude successful model develop-
ment, there are 3 reasons for the variability observed in some of our 
data. Firstly, there are ethical considerations associated with any study 
in primates. It is important to use the smallest number of animals pos-
sible; however, it was difficult to calculate the absolute minimum num-
ber required as there is no precedent or data on which to base power 
F I G U R E  4   Measurement of kidney 
fibrosis in cynomolgus monkey UUO 
model. Images of PSR- stained sections 
were analyzed using Definiens Tissue 
Studio software. Cortical area and area 
covered by red in the kidney cortex were 
quantified. (A) PSR staining. Fibrosis levels 
are expressed as the percentage of red 
(collagen) in the cortical areas. (B) Kidney 
hydroxyproline. Levels of hydroxyproline 
are expressed as µmol per mg protein. 
Raw data are presented with the line 
indicating the mean. * and ** indicate 
p < .05 and p < .01, respectively (one- way 
ANOVA). ECM, extracellular matrix; PSR, 
picrosirius red; UUO, unilateral ureteral 
obstruction
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F I G U R E  5   Changes in TG2 in cynomolgus monkey UUO kidneys. In situ TG activity (A) was detected on unfixed kidney cryostat sections 
by the incorporation of biotin cadaverine, which was revealed using a streptavidin- Alexa 555 conjugate. TG activity is represented by yellow 
and nuclei stained as blue. Extracellular TG2 (B) was detected on unfixed kidney cryostat sections. TG2 antigen is represented by green 
and nuclei stained as blue. In situ TG activity (C) and extracellular TG2 (D) in the kidney cortex was quantified using Definiens Tissue Studio 
software. Levels of activity and TG2 expression were calculated by measuring the area of yellow and green staining. Values were corrected 
for cell number by calculating this as a fraction of the blue staining of nuclei. ε- (γ- glutamyl)- lysine crosslink (E) was measured by releasing the 
dipeptide from 10 mg protein using exhaustive proteolytic digestion followed by cation exchange chromatography on an amino acid analyzer 
(Biochrom). Raw data are presented with the line indicating the mean. * and ** indicate p < .05 and p < .01, respectively (one- way ANOVA). 
TG, transglutaminase; UUO, unilateral ureteral obstruction
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calculations. Furthermore, establishing which timepoints to investigate 
proved challenging, given the limited data available. After reviewing 
early unpublished pilot work performed by Prisys Biotechnologies on 
4 animals, it was decided that 3 animals at 4 timepoints would be used. 
This small number of animals used makes it hard to draw definitive con-
clusions on the data due to the variation in their responses. Secondly, 
it was our aim to develop a model in adult animals (7– 8 years old) to 
more accurately model human disease. However, adult animals are 
more likely to have preexisting diseases; as such, all animals were pre-
screened for serum creatinine, blood urea nitrogen, and urine protein 
using a test strip, and only animals with results within a normal range 
studied. However, in some of the sections from sham animals, there 
were still some lesions with tubular dilation that exceeded that ex-
pected of 7- to 8- year- old monkeys. If these were also present in some 
of the animals receiving UUO, the rate and level of disease post- UUO 
may have been affected. In hindsight, the urine test strip- based screen-
ing process had insufficient sensitivity and resolution to detect existing 
kidney damage. To better standardize the baseline clinical parameters 
of the kidney, more sophisticated quantitative assays to measure levels 
of proteinuria and kidney function should be employed to allow selec-
tion of more homogeneous groups. In subsequent application of this 
model, we quantified proteinuria and protein and albumin- to- creatinine 
ratio, in samples collected 2 weeks apart; this led to exclusion of >40% 
of animals screened but significantly reduced data variability. Thirdly, 
Prisys Biotechnologies has access to study facilities on the same site 
as the breeding facilities, removing the need for animal transport and 
lowering animal stress and anxiety as their environment is unchanged. 
While this best practice approach undoubtedly lowers variability in dis-
ease stimuli, unlike laboratory rodents, cynomolgus monkeys are out-
bred. Therefore, despite reducing variability where possible, breeding 
from parents not closely related introduces genetic variation, adding 
significant heterogeneity to the system.
Despite variability in the data, we were able to make some key ob-
servations about the effect of UUO of the kidneys. Fibrotic changes 
in the kidney cortex shown by image analysis of PSR staining were 
consistent with levels of fibrosis, reaching a plateau from 4 weeks 
post- UUO. This is slightly different to the hydroxyproline data that 
showed fibrosis reached plateau at 5 weeks post- UUO, while vi-
sual histopathological assessment was progressive over the 6- week 
period. The difference between collagen measures may be due to 
medullary tissue being included when hydroxyproline was measured 
but excluded in the PSR analysis in stained sections. Visually, the 
expansion of the tubular basement membrane reached a maximum 
at around 4 weeks, whereas disease progression is more often as-
sociated with subsequent tubular atrophy. As the tubular basement 
membrane area would be the primary parameter in highcontent 
image analysis of PSR, it is not surprising to note small increases in 
staining post 4 weeks. In addition, changes in TG activity do not seem 
to chronologically match levels of extracellular TG2 in the UUO kid-
ney, with progressive TG activity over 6 weeks and TG2 antigen pla-
teauing from 4 weeks post- UUO. However, TG2 in the extracellular 
space may not be active, with studies showing rapid deactivation of 
extracellular TG224 or TG2 being kept in its inactive state by binding 
to heparan sulphate proteoglycans such as syndecan 4.25 Thus, it is 
possible that there was a higher percentage of active TG2 in the UUO 
kidney at the later stages. Importantly, levels of in situ TG activity 
were positively correlated with changes in collagen quantity.
In conclusion, this study has successfully transitioned the rodent 
UUO model of CKD to a NHP. The model progresses to completion in 
approximately 6 weeks compared with 3 weeks in mice and rat mod-
els, with a suggestion that an optimal study period for testing thera-
peutics to avoid disease plateauing would be 4 weeks. The NHP model 
demonstrates a much more aggressive tubular interstitial fibrosis than 
rodents, with a larger expansion of the tubular basement membrane 
and greater infiltration of interstitial cells giving a histological picture 
closer to obstructive disease in humans. This NHP model can be ap-
plied to test human- specific antifibrotic therapeutic molecules to de-
termine efficacy, target engagement, and pharmacokinetics.
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